The safe use of the CredibleMeds® lists of QT-prolonging medications requires awareness of any changes that are made to the lists. Therefore, we wish to inform you of the following changes.
Effective November 16, 2015
- Levomepromazine (Nosinan®, Nozinan®, Levoprome®), an antipsychotic: Added to the list with Known Risk of TdP (Torsades de Pointes).
- Delamanid (Deltyba®), a drug for tuberculosis: Added to the list with Possible Risk of TdP.
- Papaverine HCl (when given by infusion as part of heart testing): Added to the list with Known Risk of TdP.
Effective December 17, 2015
- Oxaliplatin (Eloxatin®), an anti-cancer drug: Added to the list of drugs with Known Risk of TdP.
- Asenapine(Saphris®, Sycrest®), an antipsychotic drug: Added to the list with Possible Risk of TdP.
- Hydrocodone extended release (brand names Hysingla ER and Zohydro ER): Added to the list with Possible Risk of TdP.
We are not aware of any relevant studies of the immediate release form of hydrocodone but we suggest caution as we continue to monitor the available evidence.
All six drugs have been added to the list of Drugs to Avoid in patients with Congenital Long QT Syndrome.